These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 17239704

  • 1. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
    Sabbah HN, Imai M, Cowart D, Amato A, Carminati P, Gheorghiade M.
    Am J Cardiol; 2007 Jan 22; 99(2A):41A-46A. PubMed ID: 17239704
    [Abstract] [Full Text] [Related]

  • 2. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE, Macarie C, Ruzyllo W, Bacchieri A, Valentini G, Bianchetti M, Pang PS, Harinstein ME, Sabbah HN, Filippatos GS, Gheorghiade M, HORIZON-HF investigators.
    Am J Ther; 2008 Jan 22; 15(3):231-40. PubMed ID: 18496261
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
    Ghali JK, Smith WB, Torre-Amione G, Haynos W, Rayburn BK, Amato A, Zhang D, Cowart D, Valentini G, Carminati P, Gheorghiade M.
    Am J Cardiol; 2007 Jan 22; 99(2A):47A-56A. PubMed ID: 17239705
    [Abstract] [Full Text] [Related]

  • 5. Istaroxime: a new luso-inotropic agent for heart failure.
    Mattera GG, Lo Giudice P, Loi FM, Vanoli E, Gagnol JP, Borsini F, Carminati P.
    Am J Cardiol; 2007 Jan 22; 99(2A):33A-40A. PubMed ID: 17239702
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
    Micheletti R, Palazzo F, Barassi P, Giacalone G, Ferrandi M, Schiavone A, Moro B, Parodi O, Ferrari P, Bianchi G.
    Am J Cardiol; 2007 Jan 22; 99(2A):24A-32A. PubMed ID: 17239701
    [Abstract] [Full Text] [Related]

  • 8. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
    Wehrens XH.
    Curr Opin Investig Drugs; 2007 Sep 22; 8(9):769-77. PubMed ID: 17729189
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs.
    Pagel PS, Harkin CP, Hettrick DA, Warltier DC.
    J Pharmacol Exp Ther; 1995 Oct 22; 275(1):127-35. PubMed ID: 7562540
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744).
    Micheletti R, Mattera GG, Rocchetti M, Schiavone A, Loi MF, Zaza A, Gagnol RJ, De Munari S, Melloni P, Carminati P, Bianchi G, Ferrari P.
    J Pharmacol Exp Ther; 2002 Nov 22; 303(2):592-600. PubMed ID: 12388640
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.